Analysis – Page 2 – Goldea Capital

Gold Royalty Completes US$103.5 Million Bought Deal Financing

Written by Customer Service on December 11, 2025. Posted in Public Companies.

VANCOUVER, British Columbia, Dec. 11, 2025 (GLOBE NEWSWIRE) — Gold Royalty Corp. (“Gold Royalty” or the “Company”) (NYSE American: GROY) is pleased to announce the closing of its previously announced public offering (the “Offering“) of common shares of the Company. Pursuant to the Offering, the Company issued, on a bought deal basis, 25,875,000 common shares (the “Common Shares”), including 3,375,000 Common Shares pursuant to the full exercise of the over-allotment option, at a price of US$4.00 per share, for aggregate gross proceeds of US$103.5 million. The Offering was completed pursuant to an underwriting agreement dated December 8, 2025, between the Company and a syndicate of underwriters led by National Bank Capital Markets, BMO Capital Markets, and RBC Capital Markets as joint bookrunners. As announced on December...

Surgery Partners, Inc. Announces Add-On Senior Notes Offering

Written by Customer Service on December 11, 2025. Posted in Public Companies.

BRENTWOOD, Tenn., Dec. 11, 2025 (GLOBE NEWSWIRE) — Surgery Partners, Inc. (NASDAQ:SGRY) (“Surgery Partners” or the “Company”), a leading short-stay surgical facility owner and operator, announced today that Surgery Center Holdings, Inc., a wholly owned subsidiary of the Company (the “Issuer”), intends to offer, subject to market and other considerations, an additional $425.0 million aggregate principal amount of its 7.250% senior unsecured notes due 2032 (the “Notes”). The Notes will be guaranteed (the “Guarantees”) on a senior unsecured basis by each domestic wholly-owned subsidiary of the Issuer that guarantees its obligations under its senior secured credit facilities. The notes will be issued as part of the same series as the Issuer’s 7.250% senior notes due 2032 originally issued in April 2024. Surgery Partners intends to...

Sono Group N.V. Subsidiary Sono Solar Wins European Transport Prize for Sustainability 2026 for Solar-Powered Refrigerated Vehicle Solution

Written by Customer Service on December 11, 2025. Posted in Public Companies.

Recognition alongside major OEMs underscores growing acceptance of integrated solar technology for commercial vehicles Munich, Dec. 11, 2025 (GLOBE NEWSWIRE) — Sono Group N.V. (Nasdaq: SSM) (hereafter referred to as “Sono” or the “Company”, parent company to Sono Motors GmbH, hereafter referred to as “Sono Solar” or “Subsidiary”), the solar technology company, today announced that its subsidiary Sono Solar has been awarded the European Transport Prize for Sustainability 2026 (ETPN) for its solar solution for refrigerated vehicles. Presented by the trade journal TRANSPORT, published by HUSS-VERLAG, the European Transport Prize for Sustainability honors forward-looking products and concepts that combine environmental and climate protection with economic efficiency and social responsibility in the commercial vehicle and logistics...

Streamex Corp. (NASDAQ: STEX) Acquires 9.9% Strategic Equity Stake in Royalty and Streaming Firm Empress Royalty Corp. Through a Premium Priced Share-for-Share Transaction at US$5.00 STEX with a Leading Institutional Investment Firm

Written by Customer Service on December 11, 2025. Posted in Mergers And Acquisitions.

LOS ANGELES, Dec. 11, 2025 (GLOBE NEWSWIRE) — Streamex Corp. (“Streamex” or the “Company”) (NASDAQ: STEX), a leader in institutional-grade tokenization and real-world asset infrastructure, today announced that it has acquired a 9.9% equity interest in Empress Royalty Corp. (“Empress”) (TSXV: EMPR) through a strategic share purchase from Terra Capital Natural Resources Fund Pty Ltd. (“Terra Capital”), a prominent institutional investor. Under the executed Share Purchase Agreement, Streamex acquired 12,671,297 common shares of Empress in exchange for 2,443,750 restricted common shares of Streamex at a US$5.00 STEX share price, representing a premium to the current market price of STEX and an aggregate transaction value equal to US$12,218,751. Why This Transaction Matters for Streamex Positive Deal Structure Completed at a Premium...

ZenaTech Signs Offer to Acquire a Surveying Firm in the US West Expanding Drone as a Service Footprint to Serve Precision Agriculture, Ranching and Wildfire Management

Written by Customer Service on December 11, 2025. Posted in Mergers And Acquisitions.

VANCOUVER, British Columbia, Dec. 11, 2025 (GLOBE NEWSWIRE) — ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) (“ZenaTech”), a technology business solution provider specializing in AI (Artificial Intelligence) drone, Drone as a Service (DaaS), enterprise SaaS and Quantum Computing solutions, announces it has signed an offer to acquire a surveying firm headquartered in the Mountain West/Rocky Mountain region of the US with existing licensing to operate in multiple states. The potential acquisition enhances ZenaTech’s presence in the region and capacity to provide drone-enabled advanced land surveying as well as drone services for modern crop and livestock management, wildfire management, and land stewardship. “Expanding our Drone as a Service footprint across the Mountain West/Rocky Mountain region through this potential...

Vera Bradley Announces Third Quarter Fiscal Year 2026 Results

Written by Customer Service on December 11, 2025. Posted in Earnings Releases And Operating Results.

Reclaiming Vera Bradley’s joyful optimism, while fueling operational excellence FORT WAYNE, Ind., Dec. 11, 2025 (GLOBE NEWSWIRE) — Vera Bradley, Inc. (Nasdaq: VRA) (the “Company”) today announced its financial results for the third quarter and nine month period ended November 1, 2025. Third Quarter Comments “Our third quarter results demonstrate progress in our comprehensive transformation strategy, which we have now branded as Project Sunshine, our five-pillar initiative anchored on reclaiming Vera Bradley’s joyful optimism while fueling operational excellence. Project Sunshine encompasses sharpening our brand focus, resetting our go-to-market approach, rewiring our digital ecosystem, implementing Outlet 2.0, and reimagining how we work as an organization,” said Ian Bickley, Executive Chairman of Vera Bradley. “With third quarter...

Stryker declares an $0.88 per share quarterly dividend

Written by Customer Service on December 11, 2025. Posted in Dividend Reports And Estimates.

Portage, Michigan, Dec. 11, 2025 (GLOBE NEWSWIRE) — Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.88 per share payable January 30, 2026, to shareholders of record at the close of business on December 31, 2025, representing an increase of 4.8% versus the prior year and previous quarter. “We remain confident in our ability to deliver strong financial performance, and consistent with our capital allocation priorities we are increasing our dividend to $0.88 per share,” said Kevin Lobo, Chair and Chief Executive Officer, Stryker. About Stryker Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and...

RedCloud Releases Earnings, Sets $100m Revenue Target After $50m Türkiye Deal, as AI Infrastructure Scales

Written by Customer Service on December 11, 2025. Posted in Public Companies.

H1 2025: 28% TTV Growth, 12% Revenue Growth, Liabilities Cut by $65M, Turkey Expansion Secured LONDON, Dec. 11, 2025 (GLOBE NEWSWIRE) — RedCloud Holdings plc (Nasdaq: RCT) (“RedCloud” or the “Company”) the technology company building intelligent infrastructure for global trade today reported first half results, with RedAI platform. In H1, the company added another $1.2 billion in trading volume — up 28% year-over-year. Revenue for H1 2025 reached $17.9 million, up 12% year-over-year. For full year 2025, RedCloud expects revenue of $51–53 million. The company is targeting $100 million in revenue for 2026. “We doubled our data capture. We launched in Saudi Arabia. We joined NVIDIA Connect. The $14.6 trillion FMCG industry still runs on spreadsheets and phone calls. We’re making it algorithmic. The infrastructure is...

Polyrizon Announces Promising Permeation Kinetics Supporting Advancement of Its Intranasal Naloxone Hydrogel Program

Written by Customer Service on December 11, 2025. Posted in Public Companies.

Ra’anana, Israel, Dec. 11, 2025 (GLOBE NEWSWIRE) — Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a biotechnology company focusing on the development of intranasal products, today announced new results from its ongoing preclinical evaluation of its proprietary intranasal naloxone hydrogel formulation, demonstrating promising permeation kinetics that complement the Company’s previously reported stability and mucoadhesion successes. Following the positive mucoadhesion findings-where Polyrizon’s formulation showed significantly enhanced persistence on ex-vivo nasal tissue compared to a marketed intranasal naloxone product (p < 0.0001) -the Company has completed a dedicated series of permeation studies using a validated artificial membrane system. These studies assessed the rate and extent of naloxone diffusion from...

Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT)

Written by Customer Service on December 11, 2025. Posted in Mergers And Acquisitions.

Novel first-in-class therapeutic targeting a key immune signaling pathway and the underlying cause of HIT It is the first and only potent, highly selective inhibitor of human 12-LOX in clinical testing, distinguishing it from related compounds. Orphan Drug and Fast Track designations from the FDAPONTE VEDRA, Fla., Dec. 11, 2025 (GLOBE NEWSWIRE) — Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome the limitations of current anticoagulation therapy, today announced the acquisition of VLX-1005 and related 12-lipoxygenase (12-LOX) assets from Veralox Therapeutics (“Veralox”). The acquisition immediately strengthens Cadrenal’s pipeline with a late-stage, first-in-class drug candidate targeting a critical immune signaling pathway. This acquisition addresses yet...

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals